A recent review published in eGastroenterology discusses recent advancements in understanding alcohol-associated liver ...

Hepatic fibrosis is the common result of injury to the liver from a variety of damaging mechanisms, and the accurate assessment of the degree of fibrosis is clinically important. For many years ...

PHILADELPHIA, PA — Carisma Therapeutics Inc. (Nasdaq: CARM) announced a strategic realignment of its resources, discontinuing ...

A newly published review in eGastroenterology compiles recent research on alcohol-associated liver disease (ALD), offering an overview of its pathogenesis and efforts to better understand this ...

The Company plans to nominate a development candidate for its liver fibrosis program in the first quarter of 2025, reflecting its expertise in macrophage biology and fibrotic diseases.

For the second time this year, University of Pennsylvania spinout Carisma Therapeutics is cutting jobs and narrowing its ...

A research team found out how AHCC, a standardized extract of cultured Lentinula edodes mycelia, might be able to suppress the progression of liver fibrosis.

Carisma’s second workforce reduction this year likely leaves the company with 44 full-time employees as turns its focus to ...

EDINBURGH, Scotland and LONDON, Dec. 10, 2024 /PRNewswire/ -- Resolution Therapeutics Limited ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering ...

Resources realigned to focus primarily on in vivo macrophage engineering platform ... CAR-M oncology programs as well as our internal liver fibrosis program underscore the potential to ...